Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Caroline Fileni, David Swoboda, Alexander Coltoff, Najla Al Ali, Rami Komrokji, Onyee Chan, Geoffrey Uy, Sarah Bertoli, Alessandro Isidori, Lenaig Le Clech, Mael Heiblig, Ludovic Gabellier, Patrick Lawrence, Lydia Kretschmer, Christoph Röllig, Jeffrey Lancet, Andrew Wei, David Sallman, Thomas Cluzeau

Blood (2025) 146 (Supplement 1): 3441.

https://doi.org/10.1182/blood-2025-3441

Published: 2025

Journal Articles

A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress)

Brian Ball, Stephen Strickland, Briggs Morrison, John DiPersio, Shaliny Kushwaha, Benjamin Lee, Rachel Ghiraldi, Kevin Cho, John Goll, David Sallman, Ghayas Issa

Blood (2025) 146 (Supplement 1): 3430.

https://doi.org/10.1182/blood-2025-3430

Published: 2025

Journal Articles

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood (2025) 146 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2025-3429

Published: 2025

Journal Articles

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Omar Alzarkali, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2025-3393

Published: 2025

Journal Articles

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Blood (2025) 146 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2025-2085

Published: 2025

Journal Articles

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Ekrem Turk, Fernando Bustamante, Fatima Tuz Zahra, Yu-Han Chen, Rory Shallis, Onyee Chan, Samuel Reynolds, Alison Walker, Ling Zhang, Seongseok Yun, Jeffrey Lancet, David Sallman, Rami Komrokji, Jinming Song, Eric Padron, Gabriela Hobbs, Andrew Kuykendall, Zhuoer Xie

Blood (2025) 146 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2025-3815

Published: 2025

Journal Articles

Mapping out the impact of MAP kinase in primary myelofibrosis

Samuel Reynolds, Andrew Kuykendall, David Sallman, Gary Reuther, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Alison Walker, Onyee Chan, Seongseok Yun, Eric Padron, Rory Shallis, Jeffrey Lancet, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2025-3812

Published: 2025

Journal Articles

Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia

Onyee Chan, Najla Al Ali, Seongseok Yun, David Sallman, Eric Padron, Alison Walker, Rami Komrokji, Gilmer Valdes, Jeffrey Lancet, Issam El Naqa, Yi Luo

Blood (2025) 146 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2025-4357

Published: 2025

Journal Articles

NOXA modulates tipifarnib sensitivity in myeloid leukemia cells.

Traci Kruer, Lei Sun, Ariel Quintana, Meghan Ferrall-Fairbanks, Hannah Newman, Shengyan Xiang, Maria Balasis, Surendra Neupane, Onyee Chan, David Sallman, Rami Komrokji, Jeffrey Lancet, Said Sebti, Eric Padron

Blood (2025) 146 (Supplement 1): 6956.

https://doi.org/10.1182/blood-2025-6956

Published: 2025

Journal Articles

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Nardelli, Jatinder Lamba, Jongphil Kim, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2025-5216

Published: 2025

Journal Articles

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Fnu Amisha, Jessica Shostak, Wenyi Fan, Onyee Chan, Rory Shallis, Zhuoer Xie, Alison Walker, Sameh Gaballa, Javier Pinilla-Ibarz, Eric Padron, David Sallman, Bijal Shah, Julio Chavez, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Yumeng Zhang, Todd Knepper, Andrew Kuykendall

Blood (2025) 146 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2025-3531

Published: 2025

Journal Articles

Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression

Blood (2025) 146 (Supplement 1): 788.

https://doi.org/10.1182/blood-2025-788

Published: 2025

Journal Articles

Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumor-infiltrating lymphocyte therapy

Zhuoer Xie, Surendra Neupane, Joshua Traina, Amond Sarnaik, Shari Pilon-Thomas, Patrick Innamarato, Doris Hansen, Nancy Gillis, David Sallman, Rami Komrokji, Jeffrey Lancet, Lilit Karapetyan, John Mullinax, Eric Padron

Blood (2025) 146 (Supplement 1): 5932.

https://doi.org/10.1182/blood-2025-5932

Published: 2025

Journal Articles

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg, Richard Stone, Eric Padron, David Sallman, Curtis Lachowiez, Jonathan Abbas, Abhishek Mangaonkar, Mrinal Patnaik, Marissa Timothy, Alonzo Martinez, Ewelina Morawa, Brandon Turunen, Philip Vickers, Sergio Santillana

Blood (2025) 146 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2025-3874

Published: 2025

Journal Articles

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

Zhuoer Xie, Qianxing Mo, Sarah Buckley, David Sallman, Jeffrey Lancet, Michael Savona, Rami Komrokji, Mrinal Patnaik, Daniel Wiseman, Eric Padron

Blood (2025) 146 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2025-3873

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh, Andrew Brunner, Diletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza, David Sallman, Eric Padron, Zhuoer Xie, James Foran, Cecilia Arana Yi, Hassan Alkhateeb, Mithun Shah, Rami Komrokji, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2025-3864

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress)

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Mapping out the impact of MAP kinase in primary myelofibrosis

Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia

NOXA modulates tipifarnib sensitivity in myeloid leukemia cells.

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression

Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumor-infiltrating lymphocyte therapy

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only